Compositions of protein receptor tyrosine kinase inhibitors

An intravenous unit dosage form, comprising:

• a therapeutically effective amount of a compound of
• or a salt, solvate, ester or prodrug thereof;
• and at least one pharmaceutically acceptable vehicle;
• wherein the intravenous unit dosage form is suitable for administration of about 0.01 mg/kg to about 100 mg/kg of the compound.

An intranasal unit dosage form, comprising:

• a therapeutically effective amount of a compound of
• or a salt, solvate, ester or prodrug thereof;
• and at least one pharmaceutically acceptable vehicle;
• wherein the intranasal unit dosage form is suitable for administration of about 0.01 mg to about 1 mg of the compound per kilogram of body weight.

A suppository unit dosage form, comprising:

• a therapeutically effective amount of a compound of
• or a salt, solvate, ester or prodrug thereof;
• and at least one pharmaceutically acceptable vehicle;
• wherein the suppository unit dosage form is suitable for administration of about 0.01 mg to about 50 mg of the compound per kilogram of body weight and comprises active ingredient in the rage of about 0.5% to about 10% by weight.

An intradermal, intramuscular, intraperitoneal, subcutaneous, epidural, sublingual or intracerebral unit dosage form, comprising:

• a therapeutically effective amount of a compound of
• or a salt, solvate, ester or prodrug thereof;
• and at least one pharmaceutically acceptable vehicle;
• wherein the intradermal, intramuscular, intraperitoneal, subcutaneous, epidural, sublingual or intracerebral unit dosage form is suitable for administration of about 0.001 mg to about 200 mg of the compound per kilogram of body weight.